Amylyx Pharmaceuticals Inc expected to post a loss of 52 cents a share - Earnings Preview

Amylyx Pharmaceuticals

18/02/2025 14:09

* Amylyx Pharmaceuticals Inc  AMLX.OQ   AMLX.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 20 (estimated) for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Amylyx Pharmaceuticals
Inc is
for a loss of 52 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amylyx
Pharmaceuticals Inc is $10.00​, above​ its last closing price
of $3.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.75       -0.71      -1.07     Missed  -50.7
 Jun. 30 2024  -0.64       -0.73      -0.73     Met     0
 Mar. 31 2024  0.02        -0.01      -0.12     Missed  -1,900
                                                        ​
 Dec. 31 2023  0.24        0.23       0.07      Missed  -69.3
 ​​Sep.        0.43        0.44       0.30      Missed  -31
 30 2023                                                
 Jun. 30 2023  0.08        0.10       0.31      Beat    210​
 Mar. 31 2023  -0.23       -0.24      0.02      Beat    108.3
 Dec. 31 2022  -0.82       -0.82      -0.65     Beat    20.7
 This summary was machine generated February 18 at 14:09 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)